Literature DB >> 950957

Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis.

H B Greenberg, R B Pollard, L I Lutwick, P B Gregory, W S Robinson, T C Merigan.   

Abstract

Four patients with chronic hepatitis B infection and chronic active hepatitis were treated with human leukocyte interferon. Three of them had consistently elevated levels of circulating Dane-particle markers, including Dane-particle-associated DNA polymerase activity, hepatitis B core antigen and Dane-particle-associated DNA. Parenteral interferon administration at a dosage between 6.0 X 10(3) and 17 X 10(4) U per kilogram per day was associated with a rapid and reproducible fall in all Dane-particle markers in the three patients. The suppressive effect was transient when the interferon was given for 10 days or less but appeared to be more permanent when administration was prolonged for a month or more. In addition, long-term interferon therapy was associated with a marked fall in hepatitis B surface antigen in two of three patients and a disappearance of e antigen in two of two patients. Interferon may be useful in limiting carrier infectivity or eradicating chronic infection.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 950957     DOI: 10.1056/NEJM197609022951001

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  95 in total

Review 1.  Tolerability of treatments for viral hepatitis.

Authors:  A Gervais; N Boyer; P Marcellin
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

2.  The effect of recombinant interferon-alpha on lymphocyte subpopulations and HLA-DR expression on liver tissue of HBV-positive individuals.

Authors:  Y K Yoo; J B Gavaler; K Chen; T L Whiteside; D H van Thiel
Journal:  Clin Exp Immunol       Date:  1990-11       Impact factor: 4.330

Review 3.  Clinical uses of interferons.

Authors:  Robert M Friedman
Journal:  Br J Clin Pharmacol       Date:  2007-12-07       Impact factor: 4.335

4.  Progress with hepatitis B virus-editorial review.

Authors:  W S Robinson
Journal:  West J Med       Date:  1978-02

5.  Antiviral treatment in chronic infection with hepatitis B virus.

Authors:  G Alexander; R Williams
Journal:  Br Med J (Clin Res Ed)       Date:  1986-04-05

6.  Elimination of size and charge heterogeneities of human leukocyte interferons by chemical cleavage.

Authors:  W E Stewart; L S Lin; M Wiranowska-Stewart; K Cantell
Journal:  Proc Natl Acad Sci U S A       Date:  1977-10       Impact factor: 11.205

Review 7.  Viral hepatitis: past and future of HBV and HDV.

Authors:  Emmanuel Thomas; Masato Yoneda; Eugene R Schiff
Journal:  Cold Spring Harb Perspect Med       Date:  2015-02-02       Impact factor: 6.915

8.  Effects of interferon and adenine arabinoside treatment of hepatitis B virus infection on cellular immune responses.

Authors:  B Hafkin; R B Pollard; M L Tiku; W S Robinson; T C Merigan
Journal:  Antimicrob Agents Chemother       Date:  1979-12       Impact factor: 5.191

9.  Preliminary trial of recombinant fibroblast interferon in chronic hepatitis B virus infection.

Authors:  M Eisenberg; S Rosno; G Garcia; M W Konrad; P B Gregory; W S Robinson; T C Merigan
Journal:  Antimicrob Agents Chemother       Date:  1986-01       Impact factor: 5.191

10.  Human leukocyte interferon in the treatment of varicella in children with cancer: a preliminary controlled trial.

Authors:  A M Arvin; S Feldman; T C Merigan
Journal:  Antimicrob Agents Chemother       Date:  1978-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.